Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (nivolumab) in Participants with Severe Sepsis or Septic Shock

Grants and Contracts Details

StatusFinished
Effective start/end date5/11/17 → 6/30/18

Funding

  • Bristol Myers Squibb Company: $10,000.00